AI in Cancer Diagnostics Market by Component (Hardware, Services, Software), Deployment (Cloud, On-Premise), Cancer Type, End-user - Global Forecast 2024-2030
The AI in Cancer Diagnostics Market size was estimated at USD 220.38 million in 2023 and expected to reach USD 266.28 million in 2024, at a CAGR 21.52% to reach USD 862.50 million by 2030.
Artificial Intelligence (AI) in cancer diagnostics involves the use of advanced algorithms and software to process, analyze, and interpret medical images and data for the detection, diagnosis, and prediction of cancer. These AI-driven systems are equipped with machine learning and deep learning capabilities, which enable them to learn from vast amounts of oncological data, improving their accuracy and efficiency over time. The increasing prevalence of cancer among the global population and the rising need for personalized medicine boost the adoption of AI in the healthcare sector. Moreover, proliferating adoption in several cancer screening programs worldwide, along with the exponential shift towards non-invasive cancer diagnosis, drives AI integration in cancer therapy. However, the high cost of AI-integrated cancer therapies and the shortage of trained oncologists impact the expansion of AI in the cancer diagnostics market. Furthermore, technological improvements in cancer diagnostics supported by government investments create lucrative opportunities for market growth.
Regional InsightsIn the American region, including the United States & Canada, the demand for AI-based cancer diagnostics is driven by a strong emphasis on early detection and personalized medicine. Prominent institutions and companies are investing heavily in AI research, and regulatory agencies such as the FDA are expediting approvals of AI diagnostic tools. Patent filings in AI from companies and academic institutions reflect the innovation in machine learning algorithms for imaging and genomic data analysis. Customers are generally receptive to AI-driven healthcare services, provided privacy and accuracy concerns are addressed. A host of EU countries engage in comprehensive AI research and development activities in the healthcare sector through government initiatives. The region shows a strong customer need for AI in cancer diagnostics due to aging populations and increased cancer prevalence. In terms of customer purchasing behavior, Europeans tend to favor products and services that comply with stringent GDPR regulations. In the Middle East, with substantial investments in smart health technologies, there's a growing market for AI cancer diagnostic tools. APAC region has a growing market for AI in cancer diagnostics, with its aging population driving consumer needs. In the APAC region, customers are increasingly tech-savvy and open to AI healthcare solutions, while the government's support of AI research has established a burgeoning market for AI in cancer diagnostics.
Market InsightsMarket Dynamics
The market dynamics represent an ever-changing landscape of the AI in Cancer Diagnostics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
Market Drivers
- Prevalence of cancer among the global population
- Proliferating adoption in several cancer screening programs worldwide
- Exponential shift towards non-invasive cancer diagnosis
Market Restraints
- High cost and shortage of trained oncologists
Market Opportunities
- Technological improvements in cancer diagnostics
- Government investments in using AI in cancer diagnostics and treatments
Market Challenges
- Vulnerability to cyberattacks and data breaches
Market Segmentation Analysis
- Component: High-volume testing centers prefer advanced hardware that can handle large-scale data processing with minimal error
- Cancer Type: Rising significance of AI-driven diagnostic for brain tumors due to complexity & critical need for precise tumor classification
Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
FPNV Positioning MatrixThe FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the AI in Cancer Diagnostics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share AnalysisThe market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the AI in Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent DevelopmentsOwkin Enters Collaboration Agreement With MSD to Develop AI-Powered Diagnostics for CancerBiotechnology firm Owkin has solidified a partnership with MSD, known as Merck & Co. in the United States, to pioneer AI-enhanced digital pathology diagnostics tailored for the European Union market. This groundbreaking collaboration aims to refine pre-screening methods for Microsatellite Instability-High (MSI-H), a genomic biomarker critical for prognosticating and guiding treatment in immunotherapy, specifically in cancers such as endometrial, gastric, small intestine, and biliary where MSI-H detection is currently not standard practice despite its significance.
ConcertAI Announces Agreement with Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging SolutionsConcertAI has established a pivotal multi-year strategic partnership with Memorial Sloan Kettering Cancer Center (MSK) to focus on driving the advancement and implementation of clinical AI algorithms and enhancing imaging workflow integration within clinical trials, as well as augmenting oncology clinical decisions. MSK heralds these advancements as a catalyst for precise diagnostics and better management of treatment, fueling a transformative shift within the radiology and AI community that promises a leap in cancer diagnosis and patient care.
Roche Collaborates with Ibex and Amazon Web Services to Accelerate Adoption of AI-Enabled Digital Pathology Solutions to Help Improve Cancer DiagnosesF. Hoffmann-La Roche Ltd. has announced collaborations with Ibex Medical Analytics and Amazon Web Services to enhance cancer diagnostics through the navify digital pathology platform, which integrates cutting-edge AI tools for improved accuracy and efficiency in diagnosing breast and prostate cancer. These innovative collaborations aim to streamline pathology workflows by providing secure access to AI-driven decision support, enabling pathologists to deliver precise and expedited patient care.
Strategy Analysis & RecommendationThe strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the AI in Cancer Diagnostics Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company ProfilesThe report delves into recent significant developments in the AI in Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Aiosyn B.V., Cancer Center.ai, ContextVision AB, Deep Bio Inc., Google LLC by Alphabet Inc., Ibex Medical Analytics Ltd., International Business Machines Corporation, Kheiron Medical Technologies Limited, Lifebit Biotech Ltd, Lunit Inc., Medial EarlySign, Microsoft Corporation, Mindpeak GmbH, Paige AI, Inc., PathAI, Inc., Proscia Inc., Qritive, Quantib B.V., ScreenPoint Medical BV, Siemens Healthineers AG, Tempus Labs, Inc., Therapixel, Visiopharm A/S, Viz.ai, and Xavor Corporation.
Market Segmentation & CoverageThis research report categorizes the AI in Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Component
- Hardware
- Services
- Software
- Deployment
- Cloud
- On-Premise
- Cancer Type
- Brain Tumor
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Prostate Cancer
- Skin Cancer
- End-user
- Cancer Centers
- Hospitals
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year